+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating patient characteristics, treatment patterns, and both short- and long-term outcomes in people with symptomatic obstructive hypertrophic cardiomyopathy HCM in the United States and Europe. The study focuses on patients receiving mavacamten, other treatments, or no treatment due to intolerance or previous treatment failure. The US sub-study particularly assesses mavacamtens safety, while the European sub-study evaluates both the safety and effectiveness of mavacamten in real-world settings. Participants receive treatment as prescribed by their physicians according to standard care for symptomatic obstructive HCM. One group takes mavacamten, while another receives beta-blockers, non-dihydropyridine calcium channel blockers, andor disopyramide. Some participants may be untreated due to intolerance or treatment failure. Treatments follow routine clinical care without study-driven changes. Throughout the study, participants are monitored for heart function changes, including heart failure events and left ventricular outflow tract gradients, over periods up to five years. Researchers collect data on arrhythmias, hospitalizations, mortality, and quality of life using questionnaires and biomarker tests. This observational registry captures real-world experiences to better understand treatment outcomes and patient health over time.

Age: 18Years +All Genders
101 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.

Age: 18Years +All GendersPhase 3
317 locations
S

Actively Recruiting

This trial evaluates the safety and effectiveness of intratumoral Alpha DaRT-224, a device delivering diffusing alpha-emitter radiation, in treating immunocompromised patients with cutaneous squamous cell carcinoma SCC. The study aims to measure the objective response rate ORR using RECIST v1.1 criteria and track progression-free survival PFS, overall survival OS, and local tumor control up to 12 months after treatment. It is a multicenter, single-arm, open-label clinical study involving up to 28 participants. Participants will receive DaRT seeds, which are encapsulated Radium-224 radioactive sources inserted directly into the SCC tumor. These sources emit short-lived alpha particles locally in the tumor microenvironment. The seeds remain implanted for 14 to 21 days before removal. The treatment targets tumors up to 7 cm in size with single lesions that can be fully covered by the radiation sources. The study does not include a comparison group. During the study, participants will undergo multiple CT scans and blood tests to monitor tumor response and safety. Researchers will assess the best overall tumor response starting from the time of DaRT seed removal. Adverse events related to the device will be classified and recorded according to established criteria. Patients must provide informed consent and will be followed for up to 12 months after seed insertion to evaluate survival and tumor control outcomes.

Age: 18Years +All GendersPhase Not Applicable
11 locations
E

Actively Recruiting

This research aims to evaluate the performance of the Perosphere ClotChek173 system, a hand-held, battery-operated blood coagulation device used at the point-of-care, in measuring whole blood clotting time WBCT in patients taking direct oral anticoagulants DOACs such as rivaroxaban or apixaban. The study focuses on characterizing how well this device can quantitatively assess clotting times in these patients compared to normal controls. Participants provide fresh whole blood samples taken at various times during the day to capture a range of clotting times rather than strict peak or trough measurements. The blood is loaded onto disposable cuvettes without biological reagents for testing with the Perosphere ClotChek173 device. This observational study collects these samples to analyze clotting times and device performance in relevant patient subgroups, including those with renal or hepatic impairments. During the study, participants will undergo venipuncture to provide non-citrated whole blood samples for the clotting time measurements. Researchers will evaluate the devices ability to distinguish between patients on rivaroxaban or apixaban and normal controls. Safety and patient history will be reviewed to ensure eligibility, and clotting times will be assessed on the day of sampling. The study is expected to run until June 2027, with participants involved in a single visit for sample collection and device evaluation.

Age: 18Years - 80YearsAll Genders
4 locations
P

Actively Recruiting

Researchers are evaluating a treatment approach for early-stage hormone-sensitive, HER-2 negative breast cancer with an Oncotype recurrence score of 18 or less. This Phase III trial compares breast conservation surgery with endocrine therapy alone against breast conservation surgery with both radiation and endocrine therapy. The goal is to see if skipping radiation after lumpectomy is not worse in preventing cancer recurrence in the same breast. Participants will be randomly assigned to one of two groups. One group will receive radiation therapy to the breast plus at least five years of endocrine therapy with drugs such as Tamoxifen, Anastrozole, Letrozole, or Exemestane. The other group will receive endocrine therapy only for at least five years without radiation. Radiation must start within 12 weeks of surgery if assigned. Endocrine therapy dosing and schedule are determined by the treating doctor. During the study, participants will have regular follow-ups up to five years to monitor cancer recurrence in the breast and elsewhere, survival, and breast preservation. Assessments will include clinical exams, imaging like mammograms or MRI, and pathology reviews. The main outcome is time to invasive or noninvasive breast tumor recurrence within five years. Some measures will continue through an average of 15 years, including breast conservation rates. Safety and overall health will be monitored throughout and after treatment.

Age: 50Years - 70YearsAll GendersPhase 3
832 locations
S

Actively Recruiting

Researchers are evaluating different treatment approaches for patients with newly diagnosed rectal cancer, focusing on those in rural settings. The study observes patients who choose either surgical or non-surgical management after neoadjuvant therapy, aiming to understand patient preferences, adherence to follow-up, and quality of life over approximately six years. Surgery for rectal cancer can have significant side effects, and emerging evidence suggests some patients with complete response to initial treatment may avoid surgery without worsening outcomes, though this is still under study especially in rural populations. Patients will receive one of three standard treatment options involving chemotherapy and radiation before any surgery decision. Following neoadjuvant therapy, patients are restaged using physical exams, imaging, and blood tests to assess tumor response. Those with complete response may choose between surgery or intensive non-operative follow-up, which includes frequent endoscopy and imaging. Treatment interruptions may occur for severe side effects. Operative patients undergo surgery followed by chemotherapy or surveillance, while non-operative patients complete chemotherapy or begin surveillance directly. Participants will have clinic visits and complete surveys on pain, quality of life, and satisfaction at multiple points before, during, and after treatment. Monitoring includes blood tests, endoscopy, MRI or ultrasound, and CT scans at scheduled intervals for up to five years. Researchers will measure patient treatment preferences, adherence to surveillance, and quality of life outcomes. The study is observational, tracking how these treatments impact patients in a rural healthcare context over time.

Age: 18Years +All Genders
1 location
L

Actively Recruiting

Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.

Age: 18Years +All GendersPhase 2Phase 3
1229 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
T

Actively Recruiting

Researchers are evaluating a text-based smoking cessation program for rural cancer survivors who smoke. This phase III trial compares an eight-week scheduled gradual reduction program paired with supportive text messages to a control intervention using an informational booklet. The study aims to assess which method better helps these patients quit smoking, with a focus on improving quality of life. The trial targets adults diagnosed with cancer within the past 10 years who currently smoke at least five cigarettes daily and live in rural areas. Participants are randomly assigned to one of two groups. One group follows a personalized eight-week gradual reduction schedule for smoking, supported by 12 weeks of cessation text messages. The other group receives the National Cancer Institutes Clearing the Air booklet to assist with quitting plans. Both groups are followed for six months after their quit date to evaluate outcomes. During the study, participants complete assessments including biochemical validation of smoking cessation up to six months post-quit date. Quality of life is measured at baseline, 30 days, and six months after quitting. Participants provide urine samples and must have texting capability on a phone to receive intervention messages. Safety and progress are monitored throughout, with the total participation lasting up to six months post-quit date.

Age: 18Years +All GendersPhase 3
224 locations
C

Actively Recruiting

Researchers are studying how well serum tumor marker directed disease monitoring works compared to the usual monitoring approach for patients with hormone receptor positive, HER2 negative metastatic breast cancer. This trial aims to see if monitoring patients with specific blood markers to decide when to perform scans leads to similar overall survival as the standard care. The study also explores healthcare costs and patient-reported anxiety and quality of life between these monitoring methods. Participants are randomly assigned to one of two groups. One group receives usual care with imaging at least every 12 weeks and tumor marker tests as decided by their doctor. The other group undergoes regular serum tumor marker tests every 4 to 8 weeks, and imaging is only done if these markers rise. Both groups continue their assigned monitoring until disease progression or up to 312 weeks. During the study, participants complete questionnaires about anxiety and quality of life. Researchers collect data on overall survival, healthcare costs, and patient experiences over various timeframes, including up to 312 weeks for survival and 102 weeks for patient-reported outcomes. Monitoring is consistent at facilities accessible to the study team, and participants are followed closely while on their assigned monitoring approach throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
723 locations

1-10 of 14

1